BioTelemetry, Inc. (BEAT): Price and Financial Metrics
BioTelemetry, Inc. (BEAT)
Today's Latest Price: $37.46 USD
Updated Apr 2 4:00pm
Add BEAT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
BEAT Stock Summary
- BEAT's current price/earnings ratio is 38.17, which is higher than 87.22% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for BEAT is currently 16.86, higher than 81.54% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of -2.48%, Biotelemetry Inc's debt growth rate surpasses 29.43% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Biotelemetry Inc are FNKO, HEAR, HLI, DHX, and COWN.
- Visit BEAT's SEC page to see the company's official filings. To visit the company's web site, go to www.gobio.com.
BEAT Stock Price Chart More Charts
BEAT Price/Volume Stats
| Current price | $37.46 | 52-week high | $63.24 |
| Prev. close | $35.15 | 52-week low | $27.35 |
| Day low | $35.01 | Volume | 374,739 |
| Day high | $39.35 | Avg. volume | 341,063 |
| 50-day MA | $44.32 | Dividend yield | N/A |
| 200-day MA | $44.27 | Market Cap | 1.28B |
BioTelemetry, Inc. (BEAT) Company Bio
BioTelemetry Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Patient Services, Product, and Research Services. The company is based in Malvern, Pennsylvania.
BEAT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $37.46 | $1231.96 | 3099% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Biotelemetry Inc. To summarize, we found that Biotelemetry Inc ranked in the 92th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 3114.67% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for BEAT, they are:
- In the past 4.02 years, Biotelemetry Inc has a compound free cash flow growth rate of 1.64%; that's higher than 95.47% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet suggests that 12% of the company's capital is sourced from debt; this is greater than only 23.02% of the free cash flow producing stocks we're observing.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 3036% |
| 1% | 3068% |
| 2% | 3099% |
| 3% | 3130% |
| 4% | 3162% |
| 5% | 3193% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BEAT, try SUPN, MNK, ACHC, HZNP, and LNTH.
Top Stories View All
4 “Fire & Ice” Stocks to Mellow You Out
Best & Worst Performing Stock Industries for April 2, 2020
Best & Worst Performing Small Cap Stocks for April 2, 2020
Best & Worst Performing Mid Cap Stocks for April 2, 2020
Best & Worst Performing Large Cap Stocks for April 2, 2020
View All Top Stories
Loading social stream, please wait...